Dynamic Changes of Cytokine Profiles and Virological Markers Associated With HBsAg Loss During Peginterferon Alpha-2a Treatment in HBeAg-Positive Chronic Hepatitis B Patients
ObjectiveTo explore dynamic changes of cytokines and virological markers associated with hepatitis B surface antigen (HBsAg) loss during peginterferon alpha-2a (PEG-IFN alpha-2a) treatment in hepatitis B e antigen (HBeAg) positive chronic hepatitis B (CHB) patients. MethodsIt was a single-center prospective cohort study. HBeAg-positive CHB patients were prospectively and consecutively enrolled. Cytokines were detected at baseline, week 12 and 24 of PEG-IFN treatment. HBsAg disappearance rate was the primary evaluation index at 48 weeks of PEG-IFN treatment. ResultsAmong 100 patients who completed the 48-week PEG-IFN alpha-2a treatment, 38 patients achieved serum HBeAg disappearance, 25 patients achieved HBeAg seroconversion, 9 patients achieved functional cure, 37 patients had HBsAg decline of >= 1 log IU/ml, and 8 patients produced hepatitis B surface antibody (HBsAb). Albumin (ALB), fms-like tyrosine kinase 3 ligand (FLT3-L) and interferon-alpha2 (IFN-alpha 2) in the clinical cure group were significantly lower than those in the non-clinical-cure group at baseline. After 12 weeks of treatment, HBsAg in the clinical cure group was significantly lower than that in the non-clinical-cure group (median 1.14 vs. 3.45 log10IU/ml, Z=-4.355, P < 0.001). The decrease of HBsAg and hepatitis B virus desoxyribose nucleic acid (HBV DNA) in the clinical cure group was significantly higher than that in non-clinical-cure group (median: HBsAg 1.96 vs. 0.33 log10IU/ml, Z=-4.703, P< 0.001; HBV DNA 4.49 vs.3.13 log(10)IU/ml, Z=-3.053, P=0.002). The increase of IFN-alpha 2 in the cure group was significantly higher than that in the non-clinical-cure group (497.89 vs. 344.74, Z=-2.126, P=0.034). After 24 weeks of treatment, HBsAg, HBeAg, Flt3-L, and IL-10 in the clinical cure group were significantly lower than those in the non-clinical-cure group (median: HBsAg 0.70 vs. 3.15 log(10)IU/ml, Z=-4.535, P< 0.001; HBeAg 1.48 vs. 13.72 S/CO, Z = 2.512, P = 0.012; Flt3-l 0.00 vs 2.24 pg/ml, Z = 3.137, P=0.002; IL-10 0.70 vs. 2.71 pg/ml, Z=-4.067, P < 0.001). HBsAg decreased significantly in the clinical cure group compared with non-clinical-cure group (median 3.27 vs. 0.45, Z=-4.463, P < 0.001). ConclusionDynamic changes of cytokines and virology markers during early PEG IFN alpha-2a treatment were associated with HBsAg loss in HBeAg-positive CHB patients.
基金：
Beijing Hospitals Authority Clinical medicine Development of Special Funding Support [XMLX 201706, XMLX 202127]; Digestive Medical Coordinated Development Center of Beijing Hospitals Authority [XXZ0302, XXT28]; Special Public Health Project for Health Development in Capital [2021-1G-4061, 2022-1-2172]; Beijing Science and Technology Commission [D161100002716002]; National Science and Technology Major Project of China [2017ZX10201201-001-006, 2017ZX10201201-002-006, 2018ZX10715-005-003-005]; Beijing Municipal Science & Technology Commission [Z151100004015122]
第一作者机构：[1]Capital Med Univ, Beijing Ditan Hosp, Dept Hepatol Div 2, Beijing, Peoples R China[2]Peking Univ Ditan Teaching Hosp, Dept Hepatol Div 2, Beijing, Peoples R China
共同第一作者：
通讯作者：
通讯机构：[1]Capital Med Univ, Beijing Ditan Hosp, Dept Hepatol Div 2, Beijing, Peoples R China[2]Peking Univ Ditan Teaching Hosp, Dept Hepatol Div 2, Beijing, Peoples R China
推荐引用方式(GB/T 7714)：
Li Minghui,Zhang Luxue,Xie Si,et al.Dynamic Changes of Cytokine Profiles and Virological Markers Associated With HBsAg Loss During Peginterferon Alpha-2a Treatment in HBeAg-Positive Chronic Hepatitis B Patients[J].FRONTIERS IN IMMUNOLOGY.2022,13:doi:10.3389/fimmu.2022.892031.
APA：
Li, Minghui,Zhang, Luxue,Xie, Si,Sun, Fangfang,Zeng, Zhan...&Xie, Yao.(2022).Dynamic Changes of Cytokine Profiles and Virological Markers Associated With HBsAg Loss During Peginterferon Alpha-2a Treatment in HBeAg-Positive Chronic Hepatitis B Patients.FRONTIERS IN IMMUNOLOGY,13,
MLA：
Li, Minghui,et al."Dynamic Changes of Cytokine Profiles and Virological Markers Associated With HBsAg Loss During Peginterferon Alpha-2a Treatment in HBeAg-Positive Chronic Hepatitis B Patients".FRONTIERS IN IMMUNOLOGY 13.(2022)
医学